Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.91 |
| ▸ | MEN1 | O00255 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.91 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.91 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.91 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.91 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.91 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | SNCA | P37840 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198 | 0.95 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL796941 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL29906204 | 0.84 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL5858623 | 0.84 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL10714892 | 0.83 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| Acetic Acid SCHEMBL9119537 | 0.83 | KMT2A (0.76) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL9742451 | 0.81 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL17867222 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL6544581 | 0.81 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2ADNMT1CACNA1B | |
| SCHEMBL5598124 | 0.80 | MEN1 (0.72) | ALDH1A1MEN1KMT2ADNMT1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863488-B2 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | ALCATEL-LUCENT USA INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863488-B2 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | ALCATEL-LUCENT USA INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863488-B2 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | ALCATEL-LUCENT USA INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100144086-A1 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | LUCENT TECHNOLOGIES INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144086-A1 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | LUCENT TECHNOLOGIES INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144086-A1 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | LUCENT TECHNOLOGIES INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20070154624-A1 | Synthesis of acenes and hydroxy-acenes | LUCENT TECHNOLOGIES INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070154624-A1 | Synthesis of acenes and hydroxy-acenes | LUCENT TECHNOLOGIES INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070154624-A1 | Synthesis of acenes and hydroxy-acenes | LUCENT TECHNOLOGIES INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144086-A1 | Reducing an acenequinone to an acenepolyhydrodiol by exposing to an alkoxyaluminate; 6,13-pentacenequinone reduced to 6,13-dihydropentacenediol using lithium tert-butoxyaluminumhydride; matrices for electronic devices; replaces silicon; transistors; computers; integrated circuits; solven- soluble | ACE, TTN, ACE2 | ALDH1A1 1542/4885MEN1 275/4885KMT2A 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.